TerminatedPhase 2NCT06739252
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Studying Perihilar cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University
- Principal Investigator
- Xiaodong Wang, M.D.Peking University Cancer Hospital & Institute
- Intervention
- Gemcitabine Oxaliplatin and 5FU(combination_product)
- Enrollment
- 1 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2024 – 2025
Study locations (1)
- Peing University Cancer Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06739252 on ClinicalTrials.govOther trials for Perihilar cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06986486Liver Transplantation for Unresectable Perihilar CholangiocarcinomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- RECRUITINGNANCT06850753En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant CriteriaOslo University Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT06717464Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract CancerTianjin Medical University Cancer Institute and Hospital
- RECRUITINGNANCT06493734Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar CholangiocarcinomaErasmus Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT05564403Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)National Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06178588Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic CholangiocarcinomaUniversity of Kansas Medical Center
- RECRUITINGNANCT06125769LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)Azienda Sanitaria Ospedaliera
- RECRUITINGPHASE4NCT05551299Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic TherapyUniversity of Leipzig